HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma

Melanoma Research

Volumn 24, Issue 1, 2014, Pages 88-91

  Nielsen, Trine O ^a   Poulsen, Steen S ^b   Journe, Fabrice ^c   Ghanem, Ghanem ^c   Sorensen, Boe S ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Capital Region   (Denmark)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

alternative splicing; CYT1; CYT2; epidermal growth factor; epidermal growth factor receptor; ErbB3; ErbB4; HER3; HER4; malignant melanoma

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOPLASM; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS;

EID: 84891871646     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000040     Document Type: Article

References (20)

1. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22:3138-3151.
2. Lacy KE, Karagiannis SN, Nestle FO. Advances in the treatment of melanoma. Clin Med 2012; 12:168-171.
3. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009; 41:1127-1132.
4. Hynes NE, Macdonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21:177-184.
5. Elenius K, Choi CJ, Paul S, Santiestevan E, Nishi E, Klagsbrun M. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 1999; 18:2607-2615.
6. Rakosy Z, Vizkeleti L, Ecsedi S, Voko Z, Begany A, Barok M, et al. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 2007; 121:1729-1737.
7. Wimmer E, Kraehn-Senftleben G, Issing WJ. HER3 expression in cutaneous tumors. Anticancer Res 2008; 28 (2A):973-979.
8. Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, et al. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 2008; 14:5188-5197.
9. Alonzo TA. Standards for reporting prognostic tumor marker studies. J Clin Oncol 2005; 23:9053-9054.
10. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93:387-391.
11. Nielsen TO, Sorensen S, Dagnaes-Hansen F, Kjems J, Sorensen BS. Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo. Br J Cancer 2013; 108:2291-2298.
12. Munk M, Memon AA, Goetze JP, Nielsen LB, Nexo E, Sorensen BS. Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and cultured cardiomyocytes. PLoS One 2012; 7: e40243.
13. El HP, Journe F, Wiedig M, Laios I, Sales F, Galibert MD, et al. Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients. Br J Cancer 2013; 108:1641-1647.
14. Hollmen M, Elenius K. Potential of ErbB4 antibodies for cancer therapy. Future Oncol 2010; 6:37-53.
15. Kurppa K, Elenius K. Mutated ERBB4: a novel drug target in metastatic melanoma? Pigment Cell Melanoma Res 2009; 22:708-710.
16. Rudloff U, Samuels Y. A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle 2010; 9:1487-1503.
17. Settleman J. A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin. Cancer Cell 2009; 16:278-279.
18. Paatero I, Lassus H, Junttila TT, Kaskinen M, Butzow R, Elenius K. CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecol Oncol 2013 [Epub ahead of print].
19. Ferretti E, Di ML, Gessi M, Mattei T, Greco A, Po A, et al. Alternative splicing of the ErbB-4 cytoplasmic domain and its regulation by hedgehog signaling identify distinct medulloblastoma subsets. Oncogene 2006; 25:7267-7273.
20. Boone B, Jacobs K, Ferdinande L, Taildeman J, Lambert J, Peeters M, et al. EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol 2011; 38:492-502.